Monterosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases including oncology, autoimmune, and inflammatory conditions. Utilizing the QuEEN™ discovery engine, which integrates AI-guided chemistry, structural biology, and proteomics, Monterosa identifies and designs MGDs with unparalleled selectivity, enabling access to a diverse range of validated therapeutic targets. The company boasts an industry-leading pipeline of MGDs, positioning it as a pioneer in precision medicine.
ID 2025-1166 is seeking a Director of Quality GCP to oversee all GCP activities, including quality oversight of ongoing clinical programs. This role involves strong stakeholder management, risk assessment, compliance program development, and regulatory submission support. The position requires 75% on-site presence.
Monterosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases including oncology, autoimmune, and inflammatory conditions. Utilizing the QuEEN™ discovery engine, which integrates AI-guided chemistry, structural biology, and proteomics, Monterosa identifies and designs MGDs with unparalleled selectivity, enabling access to a diverse range of validated therapeutic targets. The company boasts an industry-leading pipeline of MGDs, positioning it as a pioneer in precision medicine.
Dyne Therapeutics